Form 4: Evoke Pharma CFO Kowieski Acquires Stock Options

Mark Kowieski, CFO of Evoke Pharma, acquired stock options on August 7, 2024.

Summary

• Mark Kowieski, the Chief Financial Officer of Evoke Pharma, acquired stock options on August 7, 2024.
• The options grant Kowieski the right to buy 17,291 shares of Evoke Pharma stock at an exercise price of $5.27 per share.
• The options vest monthly over three years, starting August 7, 2024, with full vesting on the third anniversary, contingent upon continuous service to the Issuer.
• The options expire on August 6, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting confidence in the company's future performance. It's a neutral-positive signal.

Positives

• The acquisition of stock options by the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options to incentivize their executives.
• The vesting schedule of three years is also standard practice to ensure long-term commitment.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Evoke Pharma, Stock Options, Form 4, CFO, Mark Kowieski, Beneficial Ownership, EVOK